Loading clinical trials...
Loading clinical trials...
Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Conditions
Interventions
ibritumomab tiuxetan (Zevalin®)
Locations
8
United States
Loma Linda University
Loma Linda, California, United States
North County Oncology
Oceanside, California, United States
Medical Specialists of Fairfield
Fairfield, Connecticut, United States
Queens Hospital
Honolulu, Hawaii, United States
Northwest Oncology and Hematology
Elk Grove Village, Illinois, United States
Horizon Oncolgy Center
Lafayette, Indiana, United States
Start Date
June 1, 2003
Completion Date
October 31, 2005
Last Updated
August 23, 2023
NCT06510361
NCT05442515
NCT07162181
NCT06528301
NCT05824585
NCT04460235
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions